Why the study?
Does neoadjuvant trabectedin improve pathological complete response in patients with locally advanced myxoid liposarcoma?
Does neoadjuvant trabectedin improve pathological complete response in patients with locally advanced myxoid liposarcoma?
Neoadjuvant trabectedin demonstrates histological and objective response activity, making it a viable therapeutic option for locally advanced myxoid liposarcoma.
No takes yet. Share an insight, caveat, or question.
Supports activity in myxoid liposarcoma; hypothesis-generating and requires randomized trials before practice change.
Gronchi et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: